Alison Armour
Chief Medical Officer CURADH Pharmaceuticals
Alison was an experienced medical and radiation oncologist, with a doctorate in MTR, before joining industry 20 years ago. She is skilled in all stages of drug and diagnostic development. As Chief Medical Officer of Endocyte, Alison clinically developed PSMA617, designing the Phase III VISION registration trial and leading all global regulatory interactions and clinical operations. She supported investigator studies of PSMA617 in combination with DNA repair inhibitors, immune oncology and hormonal therapies as well as obtaining first regulatory approval of PSMA617 based on Phase II data prior to transition to Novartis in December 2018. The drug was approved in 2022 and is now known as Pluvicto.
Seminars
Step inside a candid, forward-looking conversation with the field’s scientific leaders as they dissect what the data has – and hasn’t – told us about radiopharmaceuticals heading into 2026. Challenge
assumptions, explore inflection points, and put your questions directly to the experts shaping the next wave of innovation, regulation, and clinical design
- Which scientific assumptions about radiopharmaceutical behavior have held up under clinical data through 2026 – and which are now clearly incomplete or wrong?
- Are current pharmacokinetic and dosimetry models sufficiently predictive for decision-making, or are we still over-relying on empirical iteration in the clinic?
- What is needed in the field to continue investment and movement?
- What lessons from recent late-stage programs should be influencing how we design first-in-human studies today?
- Does existing regulatory paradigms adequately reflect the unique risk–benefit calculus of radiopharmaceuticals, or is misalignment now a rate-limiting step?
- Which manufacturing and supply-chain constraints are a fundamentally scientific problem – and which require more infrastructural changes?
- Looking ahead, what scientific bottleneck is most likely to determine winners and failures in radiopharmaceuticals beyond 2026?
